Amneal Pharmaceuticals, Inc. $AMRX Stake Lessened by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Empirical Financial Services LLC d.b.a. Empirical Wealth Management trimmed its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 56.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 44,829 shares of the company’s stock after selling 58,643 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Amneal Pharmaceuticals were worth $449,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Amneal Pharmaceuticals by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 94,638 shares of the company’s stock valued at $793,000 after purchasing an additional 4,178 shares in the last quarter. Millennium Management LLC lifted its stake in Amneal Pharmaceuticals by 32.6% during the first quarter. Millennium Management LLC now owns 2,087,398 shares of the company’s stock worth $17,492,000 after purchasing an additional 512,842 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Amneal Pharmaceuticals in the first quarter worth $244,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Amneal Pharmaceuticals by 5.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 334,956 shares of the company’s stock valued at $2,807,000 after purchasing an additional 16,536 shares during the last quarter. Finally, CWM LLC increased its stake in Amneal Pharmaceuticals by 58.9% during the second quarter. CWM LLC now owns 23,962 shares of the company’s stock valued at $194,000 after purchasing an additional 8,882 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Truist Financial set a $15.00 price objective on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Barclays initiated coverage on Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 target price for the company. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Piper Sandler restated an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.80.

Amneal Pharmaceuticals Trading Up 1.7%

AMRX opened at $14.66 on Wednesday. The business’s 50 day moving average is $13.64 and its 200-day moving average is $11.65. The stock has a market cap of $4.61 billion, a PE ratio of 733.37 and a beta of 1.36. Amneal Pharmaceuticals, Inc. has a twelve month low of $6.68 and a twelve month high of $15.42.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.